• In September 2026, Vaxcyte, Inc. appointed veteran vaccine executive Luis Jodar, Ph.D., as Chief Medical Officer and legal leader David McAvoy, J.D., as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary, while confirming that topline Phase 3 OPUS-1 data for its VAX-31 adult pneumococcal candidate are expected by the end of October 2026.
• These hires bring deep experience in global vaccine development, regulation and commercialization, alongside a clearer timeline for a pivotal dataset that underpins Vaxcyte’s VAX-31 adult program.
• With Vaxcyte now narrowing the VAX-31 OPUS-1 Phase 3 data timeline, we’ll examine how this milestone shapes the company’s investment narrative.

Find 47 companies with promising cash flow potential yet trading below their fair value.

Vaxcyte Investment Narrative Recap

The core Vaxcyte story still rests on VAX-31 successfully moving through the OPUS Phase 3 program into an established pneumococcal market, while the company spends heavily ahead of any revenue. The sharpened OPUS-1 data timing by end of October 2026 tightens the window around the key near term catalyst, but does not change that clinical outcomes, regulatory views and future financing needs remain the biggest near term risks for shareholders.

The OPUS-1 update is the most relevant recent announcement here, since it defines when investors expect to see the first pivotal Phase 3 readout for VAX-31 in adults. With OPUS-1, OPUS-2 and OPUS-3 fully enrolled and over 6,000 adults dosed, the coming data flow could meaningfully influence how the market weighs Vaxcyte’s cash burn, manufacturing buildout and dependence on future guideline support versus its long term opportunity.

Yet investors should also recognise the risk that if OPUS-1 data are weaker than hoped in key serotypes, especially given Vaxcyte’s rising costs and finite cash runway, then...

Read the full narrative on Vaxcyte (it's free!)

Vaxcyte's narrative projects $224.6 million revenue and $28.1 million earnings by 2029. This implies earnings increasing by about $794.7 million from -$766.6 million today.

Uncover how Vaxcyte's forecasts yield a $109.00 fair value, a 78% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming Vaxcyte could reach about US$423.8 million of revenue and roughly US$46.2 million of earnings by 2029, which is far more upbeat than consensus and very sensitive to how VAX-31’s late stage data, manufacturing buildout and future guidelines ultimately evolve.

Explore 3 other fair value estimates on Vaxcyte - why the stock might be worth just $109.00!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Vaxcyte research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Vaxcyte research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vaxcyte's overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.